Skip to main content

blood Proteins for early Discrimination of dEmentias


Start Date
End Date
Total Funding
€ 1 800 000
Funding Programme
European Countries Involved
Dementia is a group of disorders characterized by severe memory loss ultimately impairing daily life activities. Major forms are Alzheimer’s disease, Lewy body dementia, and frontotemporal dementia. Each dementia type is caused by different biological factors and therefore requires a specific treatment targeting these factors. To develop effective treatment, it is required to precisely diagnose each dementia type in the earliest possible stage. bPRIDE will generate and validate blood tests for early and specific diagnosis of the major dementia types. Blood analysis is widely accepted for repetitive monitoring. To successfully achieve these aims, bPRIDE will analyze >1000 blood proteins in >1000 patients in different stages of these different dementias. This will be done using novel, extremely sensitive technologies. Specific and early diagnosis will empower patients by being timely informed. Moreover, it will allow to assign the most suitable novel treatments to the right patients, strongly improving the successful development of such potential therapies.
Project partners
VU Medical Center
Lund University
The University of Melbourne
Ulm University
Hospital de la Santa Creu i Sant Pau
University of Perugia
Charles University
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).